SGIOY Shionogi (ADR)
- 11.650
- +0.240+2.10%
Shionogi (ADR) News
Shin-Etsu, 24/3 operating profit down 29.8% to 701 billion yen
In the financial results for the fiscal year ending 2024/3 announced by Shin-Etsu Ka ＜4063＞, sales were 2,414.937 billion yen, down 14% from the previous fiscal year, and operating profit was 701,038 billion yen, down 29.8% from the same period. In the electronic materials business, the semiconductor market continued to adjust in the fall of the year before last, even in this period, but signs of bottoming out appeared. In the processing/trading/technical service business, demand for semiconductor wafer-related containers continued to be adjusted mainly for in-process use, but automotive input devices were recovering in response to a recovery in the automotive industry
Shionogi & Co Raises FY Dividend Plan to Y160.00
Shionogi & Co. Ltd. (4507.TO) PARENT Latest Revision Previous For Year to Mar 2024 Plan Year-end Y85.00 Y75.00 Annual Y160.00 Y1
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average fell drastically for the first time in 4 days, and Fast Rite was pushed down by about 126 yen per brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 25 days ago was 32 stocks with price increases, 193 stocks with price drops, and 0 stocks unchanged. The Nikkei Average fell sharply. The forward transaction was closed at 37818.11 yen (estimated turnover of 790 million shares), 641.97 yen lower (-1.67%) compared to the previous day. The US stock market was mixed on the 24th. The Dow average depreciated by 42.77 dollars (-0.11%) to 38460.92 dollars, and the Nasdaq rose 16.11 points (+ 0.10%) to 15712
Nikkei average contribution ranking (advance closing) ~ The Nikkei Average continued to rise drastically for 3 days, and TOEREC boosted by about 204 yen per brand
The number of gains and falls of the Nikkei Average constituent stocks as of closing 24 days ago was 166 stocks with price increases, 58 stocks with price drops, and 1 stock unchanged. The Nikkei Average was significantly higher and continued to rise for 3 days. The front-end transaction was closed at 38329.39 yen (estimated turnover of 880 million shares), 777.23 yen higher (+2.07%) compared to the previous day. The US stock market continues to grow. The Dow average rose 263.71 dollars (+ 0.69%) to 38503.69 dollars, and the NASDAQ rose 245.33 points (+ 1.59%) to 15696
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average continues to rise, and Fast Rite boosts by about 52 yen per brand
The number of gains and falls of the Nikkei average constituent stocks as of closing 23 days ago was 125 stocks with price increases, 94 stocks with price drops, and 6 stocks unchanged. The Nikkei Average continued to rise slightly. The front-end transaction was closed at 37538.06 yen (estimated turnover of 740 million shares), which was 99.45 yen higher (+0.27%) compared to the previous day. The US market rose on the 22nd. The Dow average rose by $253.58 (+0.67%) to $38239.98, and the Nasdaq rose 169.29 points (+1.11%) to 15451.30
Convertible Stock List (Part 1) [Parabolic Signal Convertible Stock List]
○ Purchase conversion stock list market code stock name closing price SAR Tokyo Stock Exchange Prime ＜2053＞ Chubu Feed 1173 1080 ＜2109＞ DM Mitsui Sugar 3025 2937 ＜2266＞ Rokko Butter 1453 1395 ＜2294＞ Kakiyasu Main Store 3180 3090 ＜2590＞ dyDo
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares
Shionogi & Co (TYO:4507) has completed the cancellation of 10.84 million treasury shares, equivalent to 3.53% of total outstanding shares before the cancellation, on April 17, according to its filing
ESCMID Global 2024: Shionogi Presents Real-world Data Demonstrating Efficacy of Fetcroja / Fetroja (Cefiderocol) in Critically Ill Patients With Certain Difficult-to-treat Bacterial Infections
New data from the largest European real-world evidence study of cefiderocol demonstrate positive outcomes including high rates of clinical success and day 28 survival across Gram-negative pathogens co
List of Yunlou stocks [Ichimoku equilibrium table/ Yunlou stock list]
○Cloud Top Stock List Market Code Stock Name Closing Price Advance Span A Advance Span B Tokyo Stock Exchange Prime ＜1963＞ JGC HD 1568 1462 1559.5 ＜2296＞ Ito Ham Yonekyu 4155 4147.5 3980 ＜3738＞ T-Gaia 2080 2079.25 1998 ＜4008＞ Sumitomo Seika
Reflecting the rise in US stocks, the advance of buybacks was also a heavy development in terms of appreciation
The Nikkei Average rebounded. The transaction closed at 39347.04 yen (estimated turnover of 1.56 billion shares), which rose by 354.96 yen. In response to the rise in major stock price indices in the US market over the weekend, the Nikkei Average began a rebound from the appearance that buying aimed at an autonomous rebound against the sharp decline of the previous weekend took precedence. The level was rounded up to 39617.36 yen at the end of the game. Also, since the exchange rate of yen depreciated towards the latter half of 1 dollar = 151 yen, it gave a sense of security to export-related stock purchases. However, what is the range of autonomous repulsion
FunPep --- signed an option agreement with Shionogi Pharmaceutical, increasing sales potential of tens of billion yen domestically alone
FunPep ＜4881＞ is a biotechnology venture established in 2013 for the purpose of putting the research results of functional peptides into practical use at Osaka University Graduate School of Medicine. We are working on the development of pharmaceuticals to replace expensive antibody pharmaceuticals using antibody-inducing peptide technology based on functional peptides developed independently. Also, in 2022/10, Anti-Aging Peptide Co., Ltd. (currently FunPep Health Care Co., Ltd.) became a subsidiary for cosmetics and other products other than pharmaceuticals
Taihei Electric, TOKYO BASE, etc.
＜1887＞Japan Land Development Co., Ltd. Xymax Group Stock Holding Ratio 5.97% → 6.29% Reporting Obligation Date 2024/04/01 ＜1904＞Taisei Onjo Co., Ltd. (API, Inc.) Stock Ownership Ratio 9.67% → 8.64% Reporting Obligation Date 2024/03/27 ＜1968＞Taihei Electric Co., Ltd. Nomura Securities Co., Ltd. Stock Ownership Ratio 10.98% → 9.8
Nikkei Average Contribution Ranking (advance closing) ~ The Nikkei Average rebounded slightly, and TOEREC boosted by about 120 yen per brand
Instead, it became 2 brands. The Nikkei Average rebounded slightly. The front-end transaction was closed at 39853.20 yen (estimated turnover 800 million shares), which was 50.11 yen higher (+0.13%) compared to the previous day. The US market was mixed on a daily basis. The Dow average closed at 39566.85 dollars (-0.60%) depreciated by 240.52 dollars, the Nasdaq closed at 16396.83, 17.37 points higher (+ 0.11%), and the S&P 500 closed at 5243.77, 10.58 points lower (-0.20%). Announced last weekend
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen
Shionogi (TYO:4507) repurchased 1.6 million shares for 11.58 billion yen in the open market from Feb. 1 to 29, according to a Tokyo Stock Exchange filing on Tuesday. The purchases were made as part of
Jefferies Adjusts Shionogi's Price Target to 7,600 Yen From 6,200 Yen, Keeps at Hold
04:09 AM EST, 03/01/2024 (MT Newswires) -- Jefferies Adjusts Shionogi's Price Target to 7,600 Yen From 6,200 Yen, Keeps at Hold
PureTech Founded Entity Akili Announces Positive Results From Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan
Express News | Akili Shares Are Trading Higher After the Company Announced That Its Japanese Partner, Shionogi & Co. Ltd, Has Submitted Akili's Digital Therapeutic SDT-001 for Marketing Approval With the Ministry of Health, Labor, and Welfare
Akili Announces Results From Shionogi's Phase 3 Clinical Trial Of Localized Version Of Akili's EndeavorRx For Pediatric ADHD Patients In Japan, Now Under Review For Nationwide Marketing Approval
Japanese Product Now Under Review for Nationwide Marketing ApprovalAkili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submi
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
Publication Includes Results of the Phase 3 Trial Evaluating Once-Daily Ensitrelvir in Asia Trial Met Primary and Key Secondary Endpoints Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer:
Shionogi Buys Back Over 8 Billion Yen Worth of Shares in January
Shionogi (TYO:4507) bought back 1.1 million shares for 8.21 billion yen in the open market from Jan. 1 to 31, according to a Tuesday bourse filing. The pharmaceutical company is allowed to reacquire u
Analysis
Price Target
No Data
